ALNY Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 1.50%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $51,381,995.84

Alnylam Pharmaceuticals Insider Trading History Chart

Alnylam Pharmaceuticals Share Price & Price History

^$232.75

▼ -1.81 (-0.77%)

As of 04/21/2025 05:00 PM ET

Days: 30 | 90 | 365

Alnylam Pharmaceuticals Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/18/2025	Kevin Joseph Fitzgerald	EVP	Sell	1,440	$251.56	$362,246.40	12,881
2/18/2025	Pushkal Garg	CMO	Sell	1,548	$251.67	$389,585.16	11,989
2/14/2025	Jeffrey V. Poulton	CFO	Sell	967	$255.17	$246,749.39	32,786
2/14/2025	Kevin Joseph Fitzgerald	EVP	Sell	663	$255.21	$169,204.23	14,321
2/14/2025	Pushkal Garg	CMO	Sell	1,561	$255.17	$398,320.37	13,537
2/14/2025	Yvonne Greenstreet	CEO	Sell	1,213	$255.17	$309,521.21	81,526
1/27/2025	Pushkal Garg	CMO	Sell	52,592	$285.00	$14,988,720.00	11,989
1/23/2025	Phillip A. Sharp	Director	Sell	11,250	$275.00	$3,093,750.00
12/12/2024	Pushkal Garg	CMO	Sell	1,752	$251.00	$439,752.00	15,705
11/26/2024	Pushkal Garg	CMO	Sell	1,682	$250.98	$422,148.36	17,457
11/26/2024	Tolga Tanguler	EVP	Sell	1,469	$250.98	$368,689.62	13,191
11/26/2024	Yvonne Greenstreet	CEO	Sell	5,219	$250.98	$1,309,864.62	78,880
8/20/2024	Yvonne Greenstreet	CEO	Sell	15,000	$280.00	$4,200,000.00	73,441
8/6/2024	Dennis A. Ausiello	Director	Sell	20,250	$262.00	$5,305,500.00	136
8/1/2024	Yvonne Greenstreet	CEO	Sell	15,148	$270.00	$4,089,960.00	73,441
7/11/2024	Yvonne Greenstreet	CEO	Sell	7,093	$261.00	$1,851,273.00	73,441
6/25/2024	Jeffrey V. Poulton	CFO	Sell	1,605	$231.00	$370,755.00	28,892
6/25/2024	Kevin Joseph Fitzgerald	EVP	Sell	1,198	$230.99	$276,726.02	14,181
6/25/2024	Pushkal Garg	CMO	Sell	2,103	$230.99	$485,771.97	15,609
6/25/2024	Yvonne Greenstreet	CEO	Sell	8,301	$230.99	$1,917,447.99	80,534
6/24/2024	David E. I. Pyott	Director	Sell	32,450	$220.69	$7,161,390.50	136
5/29/2024	Amy W. Schulman	Director	Sell	21,700	$148.60	$3,224,620.00	8,436
12/27/2023	Michael W. Bonney	Director	Sell	30,000	$195.00	$5,850,000.00	16,029
8/7/2023	Pushkal Garg	CMO	Sell	4,166	$183.89	$766,085.74	4,345
8/4/2023	Jeffrey V. Poulton	CFO	Sell	3,460	$185.85	$643,041.00	15,873
8/4/2023	Pushkal Garg	CMO	Sell	3,461	$185.85	$643,226.85	8,511
8/4/2023	Yvonne Greenstreet	CEO	Sell	4,057	$185.85	$753,993.45	35,216
4/27/2023	Akshay Vaishnaw	President	Sell	2,392	$194.59	$465,459.28	17,890
4/27/2023	Jeffrey V. Poulton	CFO	Sell	977	$194.59	$190,114.43	11,706
4/27/2023	Pushkal Garg	CMO	Sell	1,839	$194.59	$357,851.01	6,800
4/27/2023	Tolga Tanguler	EVP	Sell	1,476	$194.59	$287,214.84	1,801
4/27/2023	Yvonne Greenstreet	CEO	Sell	7,615	$194.59	$1,481,802.85	30,332
4/6/2023	Indrani Lall Franchini	EVP	Sell	3,500	$210.00	$735,000.00
3/3/2023	Pushkal Garg	CMO	Sell	18,072	$200.00	$3,614,400.00	4,345
2/2/2023	Indrani Lall Franchini	EVP	Sell	1,675	$226.01	$378,566.75	3,500
8/5/2022	Tolga Tanguler	EVP	Sell	1,841	$218.16	$401,632.56
8/3/2022	Tolga Tanguler	EVP	Sell	1,754	$210.00	$368,340.00	3,629
7/5/2022	Tolga Tanguler	EVP	Sell	1,754	$150.00	$263,100.00	1,754

See Full Table

SEC Filings (Institutional Ownership Changes) for Alnylam Pharmaceuticals (NASDAQ:ALNY)

92.97% of Alnylam Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Alnylam Pharmaceuticals Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
4/21/2025	Blue Trust Inc.	1,158	$0.31M	0.0%	+33.9%	0.001%
4/21/2025	Envestnet Portfolio Solutions Inc.	867	$0.23M	0.0%	-58.0%	0.001%
4/17/2025	QRG Capital Management Inc.	1,949	$0.53M	0.0%	+97.9%	0.001%
4/17/2025	Brighton Jones LLC	1,209	$0.33M	0.0%	+17.2%	0.001%
4/17/2025	Exchange Traded Concepts LLC	3,715	$1M	0.0%	-3.1%	0.003%
4/16/2025	Wealth Enhancement Advisory Services LLC	14,404	$3.89M	0.0%	+14.6%	0.011%
4/16/2025	Everhart Financial Group Inc.	1,787	$0.48M	0.1%	+12.0%	0.001%
4/16/2025	NorthCrest Asset Manangement LLC	1,196	$0.32M	0.0%	N/A	0.001%
4/16/2025	Tobam	3,366	$0.91M	0.4%	-71.4%	0.003%
4/16/2025	GraniteShares Advisors LLC	2,110	$0.57M	0.4%	-6.8%	0.002%
4/16/2025	Fortitude Family Office LLC	500	$0.14M	0.0%	N/A	0.000%
4/15/2025	Bannerman Wealth Management Group LLC	2,729	$0.74M	0.6%	+96.2%	0.002%
4/15/2025	Assenagon Asset Management S.A.	6,405	$1.73M	0.0%	-67.8%	0.005%
4/15/2025	Handelsbanken Fonder AB	116,683	$31.51M	0.1%	+114.7%	0.090%
4/15/2025	SG Americas Securities LLC	132,960	$35.90M	0.1%	+7,876.0%	0.102%
4/15/2025	Accurate Wealth Management LLC	2,483	$0.67M	0.1%	N/A	0.002%
4/15/2025	GAMMA Investing LLC	616	$0.17M	0.0%	+14.3%	0.000%
4/14/2025	Pallas Capital Advisors LLC	6,635	$1.79M	0.1%	+94.7%	0.005%
4/14/2025	Wedmont Private Capital	1,592	$0.43M	0.0%	+7.2%	0.001%
4/14/2025	TB Alternative Assets Ltd.	9,168	$2.48M	0.6%	N/A	0.007%
4/11/2025	Gateway Investment Advisers LLC	6,540	$1.77M	0.0%	-11.4%	0.005%
4/11/2025	E. Ohman J or Asset Management AB	5,800	$1.57M	0.0%	-4.9%	0.004%
4/10/2025	Whipplewood Advisors LLC	105	$28K	0.0%	+208.8%	0.000%
4/9/2025	Merit Financial Group LLC	5,314	$1.44M	0.0%	+113.0%	0.004%
4/8/2025	Rhumbline Advisers	181,463	$49M	0.0%	+1.0%	0.139%
4/7/2025	Summit Global Investments	3,145	$0.85M	0.1%	N/A	0.002%
4/7/2025	GAMMA Investing LLC	166,332	$44.91M	0.0%	+30,759.4%	0.128%
4/3/2025	Versant Capital Management Inc	336	$91K	0.0%	+76.8%	0.000%
3/18/2025	California State Teachers Retirement System	196,362	$46.21M	0.1%	+2.6%	0.152%
3/17/2025	Wealth Enhancement Advisory Services LLC	12,566	$2.96M	0.0%	+94.7%	0.010%
3/14/2025	Lansforsakringar Fondforvaltning AB publ	42,544	$10.01M	0.1%	N/A	0.033%
3/7/2025	Bannerman Wealth Management Group LLC	1,391	$0.33M	0.3%	N/A	0.001%
3/4/2025	Siemens Fonds Invest GmbH	3,245	$0.76M	0.0%	+137.7%	0.003%
2/28/2025	Park Square Financial Group LLC	121	$28K	0.0%	N/A	0.000%
2/28/2025	Universal Beteiligungs und Servicegesellschaft mbH	124,360	$29.26M	0.1%	N/A	0.096%
2/20/2025	Mackenzie Financial Corp	8,859	$2.09M	0.0%	-55.0%	0.007%
2/19/2025	GF Fund Management CO. LTD.	2,708	$0.64M	0.0%	N/A	0.002%
2/19/2025	Public Employees Retirement System of Ohio	44,257	$10.41M	0.0%	-8.6%	0.034%
2/18/2025	GTS Securities LLC	1,163	$0.27M	0.0%	-83.2%	0.001%
2/18/2025	Orion Capital Management LLC	3,340	$0.79M	0.3%	-2.5%	0.003%
2/18/2025	Focus Partners Advisor Solutions LLC	862	$0.20M	0.0%	N/A	0.001%
2/17/2025	USS Investment Management Ltd	26,366	$6.21M	0.0%	-19.8%	0.020%
2/17/2025	Voloridge Investment Management LLC	16,776	$3.95M	0.0%	-91.4%	0.013%
2/17/2025	Worldquant Millennium Advisors LLC	150,191	$35.34M	0.2%	+156.6%	0.116%
2/17/2025	Zurich Insurance Group Ltd FI	27,977	$6.58M	0.1%	N/A	0.022%
2/17/2025	Vident Advisory LLC	1,327	$0.31M	0.0%	+21.2%	0.001%
2/17/2025	Soleus Capital Management L.P.	76,800	$18.07M	1.1%	+29.3%	0.060%
2/17/2025	Two Sigma Advisers LP	78,800	$18.54M	0.0%	-23.6%	0.061%
2/17/2025	Two Sigma Investments LP	107,117	$25.21M	0.1%	+459.4%	0.083%
2/17/2025	Tidal Investments LLC	13,188	$3.10M	0.0%	-35.8%	0.010%
2/17/2025	Tema Etfs LLC	16,323	$3.84M	1.6%	N/A	0.013%
2/17/2025	Siemens Fonds Invest GmbH	3,245	$0.76M	0.0%	+137.7%	0.003%
2/17/2025	Shell Asset Management Co.	5,992	$1.41M	0.1%	-3.3%	0.005%
2/17/2025	Silvercrest Asset Management Group LLC	4,891	$1.15M	0.0%	N/A	0.004%
2/17/2025	Rafferty Asset Management LLC	52,817	$12.43M	0.0%	-17.3%	0.041%
2/17/2025	ProShare Advisors LLC	6,110	$1.44M	0.0%	-19.5%	0.005%
2/17/2025	Quantinno Capital Management LP	4,556	$1.07M	0.0%	+35.4%	0.004%
2/17/2025	Parkman Healthcare Partners LLC	38,672	$9.10M	1.2%	+51.7%	0.030%
2/17/2025	Nissay Asset Management Corp Japan ADV	15,947	$3.80M	0.0%	+2.1%	0.012%
2/17/2025	OMERS ADMINISTRATION Corp	5,252	$1.24M	0.0%	+20.4%	0.004%
2/17/2025	Orbimed Advisors LLC	415,600	$97.80M	2.2%	+66.0%	0.322%
2/17/2025	MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.	14,731	$3.47M	0.0%	-42.9%	0.011%
2/17/2025	LMR Partners LLP	11,901	$2.80M	0.0%	-82.4%	0.009%
2/17/2025	Laird Norton Wetherby Wealth Management LLC	1,147	$0.27M	0.0%	-15.1%	0.001%
2/17/2025	Integral Health Asset Management LLC	45,000	$10.59M	0.9%	+80.0%	0.035%
2/17/2025	Investment Management Corp of Ontario	7,099	$1.67M	0.1%	+0.6%	0.006%
2/17/2025	Janus Henderson Group PLC	210,080	$49.44M	0.0%	-4.2%	0.163%
2/17/2025	Gotham Asset Management LLC	10,924	$2.57M	0.0%	-37.8%	0.008%
2/17/2025	Graham Capital Management L.P.	2,350	$0.55M	0.0%	-34.9%	0.002%
2/17/2025	Focus Partners Wealth	4,427	$1.04M	0.0%	+245.1%	0.003%
2/17/2025	Ellevest Inc.	1,424	$0.34M	0.0%	-24.0%	0.001%
2/17/2025	Ethic Inc.	4,886	$1.15M	0.0%	+22.9%	0.004%
2/17/2025	Ensign Peak Advisors Inc	76,464	$17.99M	0.0%	-5.1%	0.059%
2/17/2025	FORA Capital LLC	12,698	$2.99M	0.3%	N/A	0.010%
2/17/2025	Frontier Capital Management Co. LLC	104,718	$24.64M	0.2%	-5.9%	0.081%
2/17/2025	Driehaus Capital Management LLC	33,480	$7.88M	0.1%	+3.5%	0.026%
2/17/2025	Colonial Trust Co SC	150	$35K	0.0%	N/A	0.000%
2/17/2025	Corton Capital Inc.	946	$0.22M	0.1%	N/A	0.001%
2/17/2025	Casdin Capital LLC	140,000	$32.94M	2.2%	-17.6%	0.109%
2/17/2025	Cetera Investment Advisers	4,770	$1.12M	0.0%	+66.3%	0.004%
2/17/2025	BOKF NA	381	$91K	0.0%	+592.7%	0.000%
2/17/2025	Bridger Management LLC	41,182	$9.69M	5.2%	+11.2%	0.032%
2/17/2025	Brevan Howard Capital Management LP	1,333	$0.31M	0.0%	+3.4%	0.001%
2/17/2025	Captrust Financial Advisors	6,414	$1.51M	0.0%	+32.7%	0.005%
2/17/2025	Beck Bode LLC	56,017	$13.18M	2.4%	N/A	0.043%
2/17/2025	Bellevue Group AG	770,268	$181.25M	3.5%	-4.8%	0.597%
2/14/2025	Mercer Global Advisors Inc. ADV	2,600	$0.61M	0.0%	N/A	0.002%
2/14/2025	Itau Unibanco Holding S.A.	171	$40K	0.0%	-44.5%	0.000%
2/14/2025	Caisse DE Depot ET Placement DU Quebec	10,018	$2.36M	0.0%	-60.4%	0.008%
2/14/2025	Comerica Bank	13,991	$3.29M	0.0%	+631.7%	0.011%
2/14/2025	Voleon Capital Management LP	37,181	$8.75M	0.6%	N/A	0.029%
2/14/2025	Utah Retirement Systems	21,325	$5.02M	0.1%	+1.9%	0.017%
2/14/2025	Schonfeld Strategic Advisors LLC	127,000	$29.88M	0.2%	+355.7%	0.098%
2/14/2025	AQR Capital Management LLC	813,356	$191.39M	0.2%	+60.9%	0.631%
2/14/2025	Northern Trust Corp	878,860	$206.81M	0.0%	+19.6%	0.681%
2/14/2025	The Manufacturers Life Insurance Company	109,102	$25.67M	0.0%	-43.0%	0.085%
2/14/2025	Beacon Pointe Advisors LLC	935	$0.22M	0.0%	-32.0%	0.001%
2/14/2025	Public Employees Retirement Association of Colorado	13,073	$3.08M	0.0%	-2.3%	0.010%
2/14/2025	Artia Global Partners LP	56,400	$13.27M	4.7%	+61.1%	0.044%
2/14/2025	Aquatic Capital Management LLC	40,552	$9.54M	0.3%	+98.7%	0.031%

Data available starting January 2016

See Full Table

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $232.75

$228.28

$237.77

50 Day Range

MA: $249.14

$224.32

$290.70

52 Week Range

Now: $232.75

$141.98

$304.39

Volume

796,447 shs

Average Volume

872,369 shs

Market Capitalization

$30.28 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.3

Who are the company insiders with the largest holdings of Alnylam Pharmaceuticals?: Alnylam Pharmaceuticals' top insider investors include:
Yvonne Greenstreet (CEO)
Jeffrey V Poulton (CFO)
Akshay Vaishnaw (President)
Pushkal Garg (CMO)
Michael W Bonney (Director)
Kevin Joseph Fitzgerald (EVP)
Tolga Tanguler (EVP)
Amy W Schulman (Director)
David E I Pyott (Director)
Dennis A Ausiello (Director)
Phillip A Sharp (Director)
Learn More about top insider investors at Alnylam Pharmaceuticals.
Who are the major institutional investors of Alnylam Pharmaceuticals?: Alnylam Pharmaceuticals' top institutional shareholders include:
Rhumbline Advisers — 0.14%
GAMMA Investing LLC — 0.13%
SG Americas Securities LLC — 0.10%
Handelsbanken Fonder AB — 0.09%
Wealth Enhancement Advisory Services LLC — 0.01%
TB Alternative Assets Ltd. — 0.01%
Learn More about top institutional investors of Alnylam Pharmaceuticals stock.
Which major investors are selling Alnylam Pharmaceuticals stock?: In the last quarter, ALNY stock was sold by these institutional investors:
Assenagon Asset Management S.A.
Tobam
Gateway Investment Advisers LLC
E. Ohman J or Asset Management AB
GraniteShares Advisors LLC
Exchange Traded Concepts LLC
During the last year, company insiders that have sold Alnylam Pharmaceuticals company stock include:
Yvonne Greenstreet (CEO)
Jeffrey V Poulton (CFO)
Akshay Vaishnaw (President)
Pushkal Garg (CMO)
Michael W Bonney (Director)
Kevin Joseph Fitzgerald (EVP)
Tolga Tanguler (EVP)
Amy W Schulman (Director)
David E I Pyott (Director)
Learn More investors selling Alnylam Pharmaceuticals stock.
Which major investors are buying Alnylam Pharmaceuticals stock?: In the previous quarter, ALNY stock was acquired by institutional investors including:
GAMMA Investing LLC
SG Americas Securities LLC
Handelsbanken Fonder AB
TB Alternative Assets Ltd.
Pallas Capital Advisors LLC
Summit Global Investments
Merit Financial Group LLC
Accurate Wealth Management LLC